US equities
|
NVDA
$204.64
▼-4.22%
INTC
$65.76
▼-28.58%
MU
$884.74
▼-5.30%
AMZN
$240.35
▼-1.41%
AAPL
$344.63
▼-1.23%
SNDK
$1,150.89
▼-13.47%
AMD
$504.80
▼-10.88%
MSFT
$521.91
▼-1.55%
NVDA
$204.64
▼-4.22%
INTC
$65.76
▼-28.58%
MU
$884.74
▼-5.30%
AMZN
$240.35
▼-1.41%
AAPL
$344.63
▼-1.23%
SNDK
$1,150.89
▼-13.47%
AMD
$504.80
▼-10.88%
MSFT
$521.91
▼-1.55%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
CytRx Corporation - Common Stock
(OP:
CYTR
)
N/A
UNCHANGED
Last Price
Updated: 1:53 PM EDT, Oct 5, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about CytRx Corporation - Common Stock
< Previous
1
2
Next >
CytRx Notes Orphazyme’s Regulatory Update from the FDA on Arimoclomol for Niemann-Pick Disease Type C
June 18, 2021
From
CytRx Corporation
Via
Business Wire
Orphazyme Wild Party At Risk As FDA Rejects Its Rare Neurodegenerative Disease Drug
↗
June 18, 2021
Orphazyme A/S (NASDAQ: ORPH) shares, which have been extremely volatile of late, could come under pressure Friday following a regulatory setback. What Happened:...
Via
Benzinga
The Daily Biotech Pulse: Biogen Faces Another Clinical Setback, CureVac's COVID-19 Vaccine Study Fails, Moment Of Reckoning For Orphazyme
↗
June 17, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 16) Alexion Pharmaceuticals,...
Via
Benzinga
A Look At Orpahzyme's Volatility Ahead Of Thursday's PDUFA Catalyst
↗
June 16, 2021
After sobering down in the past three sessions, shares of Danish biopharma Orphazyme A/S (NASDAQ: ORPH) have taken off yet again. The Curious Case of The ‘Orphazyme Rally:...
Via
Benzinga
Why Novavax, Orphazyme, Avenue Therapeutics Shares Are Moving Monday
↗
June 14, 2021
Novavax, Inc. (NASDAQ: NVAX), Orphazyme A/S (NASDAQ: ORPH) and Avenue Therapeutics, Inc. (NASDAQ: ATXI) are among the biggest movers among biopharma stocks Monday. Novavax Finally...
Via
Benzinga
The Week Ahead In Biotech: Takeda, Blueprint Medicines, Orphazyme, Eton On The Radar Ahead Of FDA Decisions, IPOs
↗
June 13, 2021
Biotech stocks extended their gains in the week ended June 11, supported by the broader market strength and some stock-specific moves. The biggest biotech news of the week came in the form of approval...
Via
Talk Markets
The Week Ahead In Biotech: Takeda, Blueprint Medicines, Orphazyme, Eton On The Radar Ahead Of FDA Decisions, IPOs
↗
June 13, 2021
Biotech stocks extended their gains in the week ended June 11, supported by the broader market strength and some stock-specific moves. The biggest biotech news of the week came in...
Via
Benzinga
CytRx to Present at Upcoming Investor Conferences
June 02, 2021
From
CytRx Corporation
Via
Business Wire
Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates
↗
June 01, 2021
The FDA review machinery worked overtime in May, completing reviews of several drug applications. Except for stray rejections or delays, the agency churned out mostly positive...
Via
Benzinga
CytRx Comments on Quarterly Results and Year-to-Date Progress
May 13, 2021
From
CytRx Corporation
Via
Business Wire
CytRx Notes Topline Data From Trial of Arimoclomol in Amyotrophic Lateral Sclerosis
May 07, 2021
From
CytRx Corporation
Via
Business Wire
< Previous
1
2
Next >
